National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

R -- DEVELOPMENT OF STRATEGIC PLAN AND GOALS FOR OFFICE OF CLINICAL TRIALS PROMOTION SOL RFQ900034-NS DUE 011599 POC Patricia Haun, Purchasing Agent, (301) 402-4509 The National Cancer Institute (NCI) proposes to enter into a sole source purchase order with Ms. Jan Reese-Coulbourne of RC Consulting, 350 Cloud's Mill Drive, Alexandria, VA 22304, to provide guidance and clinical trial expertise in the development and marketing of a national plan for the promotion of cancer clinical research. The Office of Clinical Research Promotion (OCRP) was recently established by the Director, NCI, to develop strategic goals and plans for attracting patients to clinical trials sponsored by the Institute. OCRP projects include the development and focus group testing of informed consent forms for use by physicians and patients, negotiating with third party payers for payment of certain costs incurred in the conduct of cancer clinical trials, and the promotion and marketing of cancer clinical trials. It is imperative that this effort be accomplished in a manner that demonstrates sensitivity to the viewpoint of patients, and families of cancer patients, while achieving the overall goal of increasing accrual of cancer patients into clinical trials. Ms. Jane Reese-Coulbourne has a long history of involvement with cancer research and patient advocacy, especially with patient activities and clinical trails. Ms. Reese-Coulbourne is the former Executive Vice President of the National Breast Cancer Coalition (NBCC), a grassroots organization of more than 400 organizations and 40,000 members. She also managed the start-up of the national office and their clinical trials clearinghouse. Ms. Reese-Coulbourne is a cancer patient, has represented patient needs for many years in print, radio and television medial interviews and also speaking at various national and local meetings/conferences. She also brings to this effort extensive involvement/representation on various committees and task forces such as the National Action Plan on Breast Cancer, the Environmental Protection Agency, the Food and Drug Administration, and the National Institute of Health. In many of these capacities, Ms. Reese-Coulbourne was identified as the "patient representative". Ms. Reese-Coulbourne brings to this effort an expertise and knowledge which can not be duplicated elsewhere. Her national recognition in patient accrual and patient needs will assist immeasurably in the development of a NCI Clinical Trials Marketing Plan. This notice is for informational purposes only. It is not a solicitation of competitive proposals. Offerors who believe they are qualified for this effort may submit a qualification package. However, the package must address the areas mentioned above such as patient accrual, patient advocacy, start-up experience, grassroots involvement and national recognition by membership on various advisory committees to major research institutions and must be received in this office by 1:00 p.m. EST, on January 15, 1999. If you have any questions, please contact Patricia Haun, Purchasing Agent on (301) 402-4509. Posted 12/30/98 (W-SN284138). (0364)

Loren Data Corp. http://www.ld.com (SYN# 0040 19990104\R-0004.SOL)